Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9599 posts found.

Nanoparticles to target Alzheimer’s disease

August 10, 2011 Research and Development Alzheimer's, nanoparticles

Researchers at Lancaster University funded by the European Union are hoping to develop a new treatment for Alzheimer’s disease. Nanoparticles …
News

New MS drug shows promise for Abbott

August 10, 2011 Research and Development, Sales and Marketing Abbott, Avonex, Biogen, MS, gilenya

Biogen and Abbott’s multiple sclerosis drug daclizumab has performed well in a mid-stage trial, but two deaths marred the overall …
News

Pfizer teams up with University of California for drug discovery

August 9, 2011 Research and Development, Sales and Marketing Pfizer, academic research

Pfizer has signed a deal with the University of California to help expand its drug discovery and development programme. The …
News

Takeda and Amylin stop obesity trial

August 8, 2011 Research and Development, Sales and Marketing Amylin, Takeda

Takeda and Amylin have decided to halt further studies of its combination treatment for obesity, due to ‘evolving dynamics’ within …
News
Pfizer building

Biotica becomes new victim of Pfizer’s R&D downsizing

August 8, 2011 Research and Development, Sales and Marketing

Pfizer has pulled out of a $195 million deal with UK firm Biotica, as it continues to downsize its global …
News

Meet Wainwright Associates at the TOPRA Symposium and CPhl worldwide

August 7, 2011 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Wainwright Associates

Wainwright Associates is an independent company offering consultancy services to the pharmaceutical, medical device and healthcare industry in Product Development, …
News
Press release

Mergers and spending cuts damaging drug research

August 3, 2011 Research and Development, Sales and Marketing LaMattina, Pfizer, research productivity

Big pharma’s policy of mergers and swingeing cuts is having a devastating effect on drug research, says a former Pfizer …
News

Actelion’s MS candidate shows promise

August 2, 2011 Research and Development Actelion, MS

Actelion’s prospective multiple sclerosis pill ponesimod has cheered the company by meeting its primary endpoint in a phase IIb trial. …
News

Teva’s MS treatment disappoints

August 2, 2011 Research and Development, Sales and Marketing Laquinimod, MS, Teva

Teva and Active Biotech’s oral MS drug laquinimod has failed to meet its primary endpoint in a phase III trial. …
News

Witty backs Britain as manufacturing, R&D location

July 29, 2011 Manufacturing and Production, Research and Development GSK

GlaxoSmithKline chief executive Andrew Witty has promised to expand operations in the UK in both manufacturing and R&D, saying that …
News
GlaxoSmithKline

GSK sales down on Avandia and pandemic products

July 27, 2011 Research and Development, Sales and Marketing GSK

GlaxoSmithKline has posted a slide in revenue for the second quarter, but is buoyed by strong underlying growth. Sales were …
News

Contract research news in brief

July 27, 2011 Research and Development research and development news

PPD plays down sell-off rumours, Icon sees a steep profit decline, plus updates from Beaufort, PharmaNet, ClinStar and Biofocus/IMD. PPD …
News

BMS makes $325m biotech acquisition

July 25, 2011 Research and Development, Sales and Marketing BMS, biotech, research and development news

Bristol-Myers Squibb is to plug gaps in its pipeline by buying private biotech company Amira Pharmaceuticals for $325 million in …
News

Sanofi bags GSK’s Anne Whitaker for US role

July 25, 2011 Research and Development, Sales and Marketing appointment, research and development, sales and marketing

Sanofi has appointed Anne Whitaker president of its US pharmaceutical operations. She joins the company from GlaxoSmithKline, where she served …
Appointment
Eli Lilly & Co

Lilly presents data on failed Alzheimer’s candidate

July 21, 2011 Research and Development Alzheimer's disease, lilly, research and development news, semagacestat

Lilly has presented a review of data from semagacestat, the Alzheimer’s drug it dropped last year after disappointing results. Phase …
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026